CD38 as an immunomodulator in cancer

Future Oncol. 2020 Dec;16(34):2853-2861. doi: 10.2217/fon-2020-0401. Epub 2020 Aug 28.

Abstract

CD38 is a transmembrane glycoprotein that is widely expressed in a variety of human tissues and cells, especially those in the immune system. CD38 protein was previously considered as a cell activation marker, and today monoclonal antibodies targeting CD38 have witnessed great achievements in multiple myeloma and promoted researchers to conduct research on other tumors. In this review, we provide a wide-ranging review of the biology and function of the human molecule outside the field of myeloma. We focus mainly on current research findings to summarize and update the findings gathered from diverse areas of study. Based on these findings, we attempt to extend the role of CD38 in the context of therapy of solid tumors and expand the role of the molecule from a simple marker to an immunomodulator.

Keywords: CD38; biomarker; cancer immunotherapy; immune checkpoint therapy; immunomodulation; tumor microenvironment.

Publication types

  • Review

MeSH terms

  • ADP-ribosyl Cyclase 1 / analysis
  • ADP-ribosyl Cyclase 1 / antagonists & inhibitors
  • ADP-ribosyl Cyclase 1 / physiology*
  • Antibodies, Monoclonal / therapeutic use
  • Humans
  • Immunologic Factors / physiology*
  • Immunotherapy
  • Neoplasms / immunology*

Substances

  • Antibodies, Monoclonal
  • Immunologic Factors
  • ADP-ribosyl Cyclase 1